# A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease

> **NCT05280548** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Sanofi** · enrollment: 104 (actual)

## Conditions studied

- Fabry Disease

## Interventions

- **DRUG:** Venglustat (GZ402671)
- **DRUG:** Agalsidase alfa
- **DRUG:** Agalsidase beta (GZ419828)
- **DRUG:** Migalastat

## Key facts

- **NCT ID:** NCT05280548
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-05-03
- **Primary completion:** 2026-05-15
- **Final completion:** 2027-12-06
- **Target enrollment:** 104 (ACTUAL)
- **Last updated:** 2026-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05280548

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05280548, "A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease". Retrieved via AI Analytics 2026-08-08 from https://api.ai-analytics.org/clinical/NCT05280548. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*